- Home
- DTSS vs NLSP Comparison
DTSS vs NLSP Comparison
Compare DTSS & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- NLSP
- Stock Information
- Founded
- DTSS 2014
- NLSP 2015
- Country
- DTSS China
- NLSP Switzerland
- Employees
- DTSS N/A
- NLSP N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- NLSP Health Care
- Exchange
- DTSS Nasdaq
- NLSP Nasdaq
- Market Cap
- DTSS 16.5M
- NLSP 12.4M
- IPO Year
- DTSS N/A
- NLSP 2021
- Fundamental
- Price
- DTSS $2.05
- NLSP $2.10
- Analyst Decision
- DTSS
- NLSP
- Analyst Count
- DTSS 0
- NLSP 0
- Target Price
- DTSS N/A
- NLSP N/A
- AVG Volume (30 Days)
- DTSS 49.3K
- NLSP 275.3K
- Earning Date
- DTSS 05-14-2025
- NLSP 07-22-2025
- Dividend Yield
- DTSS N/A
- NLSP N/A
- EPS Growth
- DTSS N/A
- NLSP N/A
- EPS
- DTSS N/A
- NLSP N/A
- Revenue
- DTSS $56,255,129.00
- NLSP N/A
- Revenue This Year
- DTSS N/A
- NLSP N/A
- Revenue Next Year
- DTSS N/A
- NLSP N/A
- P/E Ratio
- DTSS N/A
- NLSP N/A
- Revenue Growth
- DTSS 144.20
- NLSP N/A
- 52 Week Low
- DTSS $1.63
- NLSP $1.30
- 52 Week High
- DTSS $3.55
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- DTSS 52.48
- NLSP 46.61
- Support Level
- DTSS $1.89
- NLSP $2.20
- Resistance Level
- DTSS $1.96
- NLSP $3.08
- Average True Range (ATR)
- DTSS 0.10
- NLSP 0.25
- MACD
- DTSS 0.01
- NLSP -0.06
- Stochastic Oscillator
- DTSS 81.80
- NLSP 8.40
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.